Tecsys (TCS) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
22 Apr, 2026Opening remarks and agenda
Meeting opened with introductions of executive leadership and directors, and outlined rules for virtual participation and Q&A session.
Agenda included procedural matters, financial review, election of directors, auditor appointment, and executive presentations.
Board and executive committee updates
Eight nominees were proposed and elected as directors to serve until the next annual meeting or until successors are appointed.
KPMG LLP was reappointed as auditors, with directors authorized to fix their remuneration.
Financial performance review
Revenue grew by 3% in 2025, with SaaS revenue up 29% and hardware revenue down 39%.
Adjusted EBITDA increased by 39% to CAD 13.4 million, driven by SaaS margin expansion.
SaaS margin rose from 50% in 2023 to 61% in 2025, with a target of 65% in 2026 and a long-term goal of 80%.
Cash and short-term investments exceeded CAD 39 million, with no debt and CAD 6.9 million in share repurchases.
Latest events from Tecsys
- Directors and auditors elected, SaaS revenue and margins up, no shareholder questions.TCS
AGM 202422 Apr 2026 - SaaS revenue rose 33%, bookings 57%, and guidance was reaffirmed amid strong governance actions.TCS
Q1 202522 Apr 2026 - SaaS revenue up 29% year-over-year, fueling record profit and strong healthcare momentum.TCS
Q4 202522 Apr 2026 - Record SaaS growth, TecsysIQ launch, and cost-saving measures drive strong Q3 results.TCS
Q3 20265 Mar 2026 - Record SaaS growth and margin gains drive strong FY2024 results and positive outlook.TCS
Q4 20243 Feb 2026 - Q2 2025 SaaS revenue up 34% year-over-year, with ARR and RPO reaching record highs.TCS
Q2 202511 Jan 2026 - SaaS revenue and profit surged in Q2 FY26, with robust healthcare pipeline and record margins.TCS
Q2 20265 Dec 2025 - Record SaaS growth and margin expansion drive strong Q3 and positive FY25 outlook.TCS
Q3 20251 Dec 2025 - SaaS revenue rose 25%, ARR and EBITDA climbed, and guidance and dividend were maintained.TCS
Q1 202620 Oct 2025